Outpatient Management of Severe Early OHSS by Administration of GnRH Antagonist in the Luteal Phase: an Observational Cohort Study

Overview

Journal Reprod Biol Endocrinol

Publisher Biomed Central

Specialties Endocrinology
Reproductive Medicine

Date 2012 Sep 4

PMID 22938051

Citations 18

Authors

George T Lainas

Efstratios M Kolibianakis

Ioannis A. Sfontouris

Ioannis Z Zorzovilis

George K Petsas

Theoni B Tarlatzi

Basil C Tarlatzis

Trifon G Lainas

Affiliations

Soon will be listed here.

Abstract

Background: Management of established severe OHSS requires prolonged hospitalization, occasionally in intensive care units, accompanied by multiple ascites punctures, correction of intravascular fluid volume and electrolyte imbalance. The aim of the present study was to evaluate whether it is feasible to manage women with severe OHSS as outpatients by treating them with GnRH antagonists in the luteal phase.

Methods: This is a single-centre, prospective, observational, cohort study. Forty patients diagnosed with severe OHSS, five days post oocyte retrieval, were managed as outpatients after administration of GnRH antagonist (0.25 mg) daily from days 5 to 8 post oocyte retrieval, combined with cryopreservation of all embryos. The primary outcome measure was the proportion of patients with severe OHSS, in whom outpatient management was not feasible.

Results: 11.3% (95% CI 8.3%-15.0%) of patients (40/353) developed severe early OHSS. None of the 40 patients required hospitalization following luteal antagonist administration and embryo cryopreservation. Ovarian volume, ascites, hematocrit, WBC, serum oestradiol and progesterone decreased significantly (P < 0.001) by the end of the monitoring period, indicating rapid resolution of severe OHSS.

Conclusions: The current study suggests, for the first time, that successful outpatient management of severe OHSS with antagonist treatment in the luteal phase is feasible and is associated with rapid regression of the syndrome, challenging the dogma of inpatient management. The proposed management is a flexible approach that minimizes unnecessary embryo transfer cancellations in the majority (88.7%) of high risk for OHSS patients.

Citing Articles

[The best evidence for the management of ovarian hyper-stimulation syndrome in patients undergoing assisted reproductive therapy].

He Y, Wang Z, Zhang Y, Jiang X, Shen X, Xu M Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024; 53(5):632-640.

PMID: 39319473 PMC: 11528148. DOI: 10.3724/zdxbyxb-2024-0349.

Fertility Preservation and Ovarian Hyperstimulation Syndrome Management in Cancer Care: A Pathophysiological Perspective on Gonadotropin-Releasing Hormone Agonists and Antagonists.

Bedoschi G, Ingold C, Navarro P Pathophysiology. 2024; 31(2):288-297.

PMID: 38921726 PMC: 11206524. DOI: 10.3390/pathophysiology31020021.

Outpatient paracentesis for the management of ovarian hyperstimulation syndrome: study protocol for the STOP-OHSS randomised controlled trial.

White D, Pye C, Ridsdale K, Dimairo M, Mooney C, Wright J BMJ Open. 2024; 14(1):e076434.

PMID: 38262643 PMC: 10806818. DOI: 10.1136/bmjopen-2023-076434.

Beyond the Umbrella: A Systematic Review of the Interventions for the Prevention of and Reduction in the Incidence and Severity of Ovarian Hyperstimulation Syndrome in Patients Who Undergo In Vitro Fertilization Treatments.

Palomba S, Costanzi F, Nelson S, Besharat A, Caserta D, Humaidan P Int J Mol Sci. 2023; 24(18).

PMID: 37762488 PMC: 10531768. DOI: 10.3390/ijms241814185.

A Personalized Management Approach of OHSS: Development of a Multiphase Prediction Model and Smartphone-Based App.

Cao M, Liu Z, Lin Y, Luo Y, Li S, Huang Q Front Endocrinol (Lausanne). 2022; 13:911225.

PMID: 35872996 PMC: 9296830. DOI: 10.3389/fendo.2022.911225.

References

RABAU E, David A, SERR D, Mashiach S, Lunenfeld B . Human menopausal gonadotropins for anovulation and sterility. Results of 7 years of treatment. Am J Obstet Gynecol. 1967; 98(1):92-8. DOI: 10.1016/0002-9378(67)90137-8. View

Lainas T, Petsas G, Stavropoulou G, Alexopoulou E, Iliadis G, Minaretzis D . Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization. Fertil Steril. 2002; 78(3):529-33. DOI: 10.1016/s0015-0282(02)03290-9. View

Asimakopoulos B, Nikolettos N, Nehls B, Diedrich K, Al-Hasani S, Metzen E . Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil Steril. 2006; 86(3):636-41. DOI: 10.1016/j.fertnstert.2006.01.046. View

Devroey P, Polyzos N, Blockeel C . An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011; 26(10):2593-7. DOI: 10.1093/humrep/der251. View

Al-Inany H, Youssef M, Aboulghar M, Broekmans F, Sterrenburg M, Smit J . Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011; (5):CD001750. DOI: 10.1002/14651858.CD001750.pub3. View

DAngelo A, Amso N . Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod. 2002; 17(11):2787-94. DOI: 10.1093/humrep/17.11.2787. View

Lainas T, Sfontouris I, Zorzovilis I, Petsas G, Lainas G, Alexopoulou E . Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Hum Reprod. 2009; 25(3):683-9. DOI: 10.1093/humrep/dep436. View

Lainas T, Sfontouris I, Zorzovilis I, Petsas G, Lainas G, Kolibianakis E . Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online. 2007; 15(4):408-12. DOI: 10.1016/s1472-6483(10)60366-5. View

Pau E, Alonso-Muriel I, Gomez R, Novella E, Ruiz A, Garcia-Velasco J . Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod. 2006; 21(6):1453-60. DOI: 10.1093/humrep/del005. View

10.

Rizk B, Aboulghar M, Smitz J, Ron-El R . The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update. 1997; 3(3):255-66. DOI: 10.1093/humupd/3.3.255. View

11.

Chen S, Chou C, Lin C, Lee H, Wu J, Lu H . Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. Hum Reprod. 2009; 25(3):757-67. DOI: 10.1093/humrep/dep432. View

12.

Soares S, Gomez R, Simon C, Garcia-Velasco J, Pellicer A . Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008; 14(4):321-33. DOI: 10.1093/humupd/dmn008. View

13.

Morris R, Paulson R, Sauer M, Lobo R . Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Hum Reprod. 1995; 10(4):811-4. DOI: 10.1093/oxfordjournals.humrep.a136044. View

14.

Humaidan P, Quartarolo J, Papanikolaou E . Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010; 94(2):389-400. DOI: 10.1016/j.fertnstert.2010.03.028. View

15.

Kolibianakis E, Schultze-Mosgau A, Schroer A, VAN Steirteghem A, Devroey P, Diedrich K . A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005; 20(10):2887-92. DOI: 10.1093/humrep/dei150. View

16.

. Ovarian hyperstimulation syndrome. Fertil Steril. 2008; 90(5 Suppl):S188-93. DOI: 10.1016/j.fertnstert.2008.08.034. View

17.

Lainas T, Sfontouris I, Zorzovilis I, Petsas G, Lainas G, Alexopoulou E . Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase. Reprod Biomed Online. 2009; 19(6):789-95. DOI: 10.1016/j.rbmo.2009.09.021. View

18.

Aboulghar M, Mansour R, Serour G, Sattar M, Amin Y, Elattar I . Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy. Obstet Gynecol. 1993; 81(1):108-11. View

19.

Griesinger G, Diedrich K, Devroey P, Kolibianakis E . GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update. 2005; 12(2):159-68. DOI: 10.1093/humupd/dmi045. View

20.

Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohi J, Simon C . The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril. 1999; 71(3):482-9. DOI: 10.1016/s0015-0282(98)00484-1. View